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In the late 1960s. aspirin was found to have platelet inhibi- 
tory effects; its role in the prevention of coronary platelet 
thrombosis, then considered the cause of heart attacks, was 
anticipated. During the 197Os, however, the antithrombotic 
effects of aspirin were viewed with pessimism, mainly be- 
cause of two factors. First, the role of coronary thrombosis 
in the pathogenesis of myocardial infarction was questioned. 
Second, the effects of platelet inhibitors (including aspirin) in 
the secondary prevention of coronary artery disease did not 
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an enthusiastic support for platelet inhibitors, especially 
aspirin, has reemerged. This renewed interest is a result of a 
better understanding of the important role of platelets and 
thrombosis in the pathogenesis of coronary disease. In 
addition, the results of better designed trials of aspirin in 
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patients with coronary disease have lent further support to 
the use of antiplatelet therapy in unstable angina, acute 
myocardial infarction, coronary angioplasty and saphenous 
vein bypass surgery. Furthermore, the role of aspirin in the 
secondary prevention of coronary and cerebrovascular dis- 
ease has become apparent and its usefulness in primary 
prevention is emerging. 
Platelets are not the only elements involved in thrombotic 
and thromboembolic processes. These processes result from 
an interaction between platelets and the coagulation and 
fibrinolytic systems. We have attempted to analyze: 1) the 
role of platelets in thrombogenesis, 2) the pharmacology of 
platelet inhibitor agents, and 3) the results of randomized 
controlled trials of platelet inhibitors in coronary artery 
disease, saphenous vein graft disease, prosthetic valve re- 
placement and cerebrovascular disease. A complete discus- 
sion of anticoagulant and fibrinolytic therapy is beyond the 
scope of this review, and has been undertaken elsewhere 
(1,2). However, specific aspects of anticoagulation and fi- 
brinolysis will be briefly mentioned when pertinent. 
Role of Platelets in Thrombogenesis 
Platelets are fragments of membrane-enclosed megakario- 
cytic cytoplasm that travel in the periphery of the circulating 
mass and do not adhere to intact endothelium. After super- 
ficial endothelial injury, only a monolayer of platelets ad- 
heres to the exposed subendothelium. When endothelial 
damage is more severe, exposure of collagen and other 
elements of the vessel wall stimulates the activation of 
platelets and the coagulation system and leads to thrombus 
formation (3). In this section, we will examine the processes 
of platelet adhesion and spreading, platelet secretion and 
aggregation and activation of the clotting system, as well as 
of endogenous inhibitors of thrombosis. 
Platelet adhesion and spreading. Platelets do not attach to 
the intact endothelium, but they firmly adhere to a disrupted 
or damaged endothelial surface (Fig. 1). Subendothelial 
collagen and fibronectin markedly stimulate platelet adhe- 
sion. Platelets adhere more avidly to collagen fibrils that lie 
deep within the vascular wall, such as in ulcerated athero- 
sclerotic plaques, than to those found immediately beneath 
the endothelium (4). Platelet membrane receptors are essen- 
tial in the process of adhesion and aggregation (Fig. 2). 
Glycoprotein Ia binds collagen at low shear rates and may 
contribute to platelet adherence to the area of damage. 
Glycoprotein Ib serves as the binding site for von Willebrand 
factor, especially at high shear rates (5). Glycoprotein IIb- 
IIIa not only plays an essential role in platelet aggregation by 
binding fibrinogen and von Willebrand factor, but also 
participates in the process of adhesion (5). 
After adhesion, platelets lose their discoid shape, form 
pseudopods and spread out over the injured surface. Parallel 
association of actin filaments leads to pseudopod formation, 
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Figure 1. Schematic representation of the microscopic phases of 
arterial thrombus formation: platelet adhesion and spreading, plate- 
let aggregation, activation of the coagulation system and thrombus 
formation and activation of the endogenous inhibitors of thrombo- 
sis. Dashed line denotes an inhibitory reaction. ADP = adenosine 
diphosphate; TxA, = thromboxane A,. 
spreading of the platelet surface membrane into a thin film, 
platelet contraction and stabilization of the hemostatic plug 
(6). 
Platelet secretion and aggregation. Platelets contain dif- 
ferent types of secretory granules including dense and alpha 
granules, lysosomes and peroxisomes (Table 1). The first 
two are particularly important in aggregation and thrombo- 
genesis. Dense granules contain adenosine diphosphate, 
serotonin, calcium and phosphate. Of these, adenosine 
diphosphate is the most important proaggregating com- 
pound. Alpha granules contain fibrinogen, fibronectin, von 
Willebrand factor, platelet factor 4, platelet-derived growth 
factor, thrombospondin and other compounds. Fibrinogen, 
von Willebrand factor and fibronectin are found not only in 
platelet granule secretions, but also in plasma. It is not yet 
known whether the platelet or the plasmatic components are 
physiologically more important in aggregation. Fibrinogen 
and von Willebrand factor bind to their receptor- 
glycoprotein IIb-IIIa--on adjacent platelets and form stable 
platelet aggregates (Fig. 2) (5,7). Platelet-derived growth 
factor is a potent mitogen and chemotactic agent for smooth 
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Figure 2. Left, Schematic representa- 
tion of the interactions among platelet 
membrane receptors (glycoproteins Ia, 
Ib and IIblIIIa). adhesive macromol- 
ecules and the disrupted vessel wall. 
Numbers indicate the different path- 
ways of platelet activation, dependent 
on I) collagen, 2) thrombin, 3) adeno- 
sine diphosphate (ADP) and serotonin, 
and 4) thromboxane A? (TxA,). Right 
The intrinsic and extrinsic systems of 
the coagulation cascade. Note the in- 
teraction between clotting factors and 
the platelet membrane. Ca = calcium; 
VWF = von Willebrand factor. 
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muscle cells; it also attracts neutrophils and is a vasocon- 
strictor (8,9). Platelet factor 4 (antiheparin factor) attracts 
neutrophiles and monocytes, perhaps serving as a stimulus 
to leukocyte accumulation in areas of endothelial injury (IO). 
The first pathway. How does the overall process of 
platelet aggregation take place? Through the action of sev- 
eral extrinsic activators such as collagen and thrombin 
(when there is vascular damage) and epinephrine, platelets 
change their shape from discs to spiny spheres. Calcium is 
then released from the dense tubular system into the cyto- 
plasm by the action of phospholipase on platelet membrane 
phosphatidylinositol. This, in turn, is associated with the 
activation of the actin-myosin system, which results in 
platelet contraction with the release of adenosine diphos- 
phate, serotonin and thromboxane AZ. It appears that colla- 
gen and thrombin not only contribute to platelet aggregation 
indirectly (through the release of the above compounds), but 
also have a direct effect on platelets, possibly through a 
platelet-activating factor (Fig. 3). For the purpose of this 
discussion, these reactions, which are dependent on collagen 
and thrombin, constitute the first pathway of platelet activa- 
tion, leading to the exposure of platelet membrane receptors. 
The second prrthway. This pathway is mediated by sero- 
Table 1. Content of Platelet Granules 
Dense granules 
Adenosine diphosphate. serotonin, calcium. phosphate 
Alpha granules 
Proteins not present in plasma: platelet-derived growth factor. platelet 
factor 4, beta-thromboglobulin 
Proteins present in plasma: fibrinogen, von Willebrand factor, 
fibronectin, albumin, thrombospondin, platelet factor 5 
Lysosomes 
Acid hydrolases, cathepsin D,E 
Peroxisomes 
Catalase 
tonin and adenosine diphosphate, which are released from 
the platelet-dense granules after contraction. Adenosine 
diphosphate is a potent inducer of platelet aggregation in the 
presence of calcium and fibrinogen. It stimulates neighboring 
platelets to expose their binding sites to fibrinogen and von 
Willebrand factor (7), thus promoting aggregation. The high 
shear stress found in stenotic areas and at branching points 
within the arterial tree facilitates the deposition of platelets 
and the development and growth of thrombus (11). Further- 
more, the turbulence present in these areas promotes red cell 
lysis, with the subsequent release of adenosine diphosphate, 
which in turn activates platelets and promotes their aggre- 
gation. 
7’hc> third puthway. This pathway is mediated by arachi- 
donic acid, which is released from the platelet membrane by 
the action of phospholipase A2 on phosphatidylcholine. 
Cyclooxygenase converts arachidonic acid into the proag- 
gregating prostaglandin endoperoxide intermediates (pros- 
taglandins G, and H,); thromboxane A2 is formed by the 
action of thromboxane synthetase, particularly on prosta- 
glandin HZ. Thromboxane A2 is both a potent platelet- 
aggregating substance and a vasoconstrictor. It stimulates 
platelet aggregation by promoting the mobilization of intra- 
cellular calcium and causing a conformational change in the 
glycoprotein IIb-IIIa complex, which results in the exposure 
of previously occult fibrinogen and von Willebrand factor 
binding sites (12,13). 
In summrr~. collagen thnt becomes exposed after vessel 
injury, thromhin generated by activution of the coagulation 
system and products of platelet secretion such as adenosine 
diphosphate and thromboxane A2 can enhance the throm- 
botic process by stimulating adjacent platelets and facilitat- 
ing the exposure of their membrane receptors to fibrinogen 
and von Willebrand factor. These reactions, in turn, promote 
further platelet aggregation and thrombus growth. 
Prostcrcyclin. In contrast, vascular tissue synthesizes 
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Figure 3. Mechanisms of platelet activation and presumed sites of 
action of various platelet inhibitor agents. Platelet agonists lead to 
the mobilization of calcium (Ca”), which functions as a mediator of 
platelet activation through metabolic pathways dependent on aden- 
osine diphosphate (ADP), thromboxane A, (TXA,), thrombin and 
collagen. Cyclic adenosine monophosphate (CAMP) inhibits calcium 
mobilization from the dense tubular system. Note that thrombin and 
collagen may independently activate platelets by means of platelet- 
activating factor. Asterisk (*) indicates a platelet inhibitor. Dashed 
line indicates a presumed site of drug action. ATP = adenosine 
triphosphate; EPA = eicosapentaenoic acid; PGE, = prostaglandin 
E,; PGH, = prostaglandin H,; PGI, = prostaglandin I,. 
prostacyclin (prostaglandin I,) from arachidonic acid (14) or 
platelet-derived prostaglandin GZ. Prostacyclin acts as a 
potent inhibitor of platelet aggregation by stimulating adenyl 
cyclase, which leads to an increase in cyclic adenosine 
monophosphate levels and a reduction in calcium mobiliza- 
tion from intracellular storage sites (15). Prostaglandins, 
cyclic adenosine monophosphate and intracellular calcium 
control platelet activity by interacting in a number of com- 
plex ways. Cyclic adenosine monophosphate inhibits both 
platelet secretion and aggregation, and its concentration 
depends on the activity of two enzymes (adenyl cyclase and 
phosphodiesterase). Whereas prostacyclin inhibits platelet 
aggregation by stimulating adenyl cyclase, thromboxane A, 
has the opposite biologic effect. 
Leukotrienes. The other metabolic pathway of arachi- 
donic acid is mediated by the enzyme lipoxygenase, which 
results in the production of leukotrienes. These compounds 
have been associated with a number of pathophysiologic 
reactions including immune-mediated reactions, chemotaxis 
for neutrophils, constrictor actions on various smooth mus- 
cle beds (particularly the coronary vessels) and platelet 
aggregation. Our understanding of the effects of leukotrienes 
on the cardiovascular system is evolving. 
Activation of the clotting system. In addition to adhering 
to the injured vascular wall and forming aggregates, acti- 
vated platelets markedly accelerate the generation of throm- 
bin (16). Perhaps by rearranging their surface lipoproteins 
during contraction, activated platelets promote the interac- 
tion of clotting factors (16). It is on the platelet surface where 
the interactions between factors IX and VIII and factors X 
and V occur (Fig. 2). Furthermore, the binding of thrombin 
and other activated clotting factors to platelets may protect 
them from inhibition (17). 
The intrinsic coagulation pathway is initiated when blood 
comes in contact with the deendothelialized vascular sur- 
face. In the extrinsic pathway, a lipoprotein called tissue 
factor or tissue thromboplastin is released into the plasma 
and initiates the coagulation process. Aside from the intrin- 
sic and extrinsic activation, both the negatively charged 
phospholipids on the platelet surface and calcium are essen- 
tial for maximal activation of factor X. Once factor X is 
activated, prothrombin is converted to thrombin, which 
cleaves fibrinogen to fibrin and activates factor XIII. This 
factor catalyzes the crosslinking reaction of fibrin. Polymer- 
ized fibrin, in turn, stabilizes the platelet mass and allows the 
arterial thrombus to withstand the high intravascular pres- 
sure and force of blood flow. In addition, it should be 
emphasized that thrombin itself is a powerful platelet acti- 
vator. 
Endogenous inhibitors of thrombus formation. During 
platelet activation and fibrin formation, endogenous mecha- 
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nisms tend to limit thrombus formation (Fig. 1). The most 
important of these are prostacyclin (discussed earlier), anti- 
thrombin III, protein C and the fibrinolytic system. Prosta- 
cyclin inhibits platelet aggregation by increasing platelet 
cyclic adenosine monophosphate and reducing the mobiliza- 
tion of calcium from its storage sites (15). Antithrombin III is 
an important endogenous anticoagulant that inhibits throm- 
bin and activated factors IX, X, XI and XII (18). Its 
inhibitory action is markedly increased by heparin. 
Plasminogen activators and inhibitors. Protein C is acti- 
vated by the association of thrombin with thrombomodulin. 
In addition to being a potent anticoagulant, protein C ini- 
tiates fibrinolysis by activating plasminogen and neutralizing 
a circulating inhibitor of tissue plasminogen activator (19). 
Once activated, plasminogen is converted to plasmin, which 
hydrolizes fibrin into soluble fragments and degrades fibrin- 
ogen, prothrombin and factors VIII and V (20). The proteo- 
lytic activity of plasmin remains localized to the fibrin 
surface; as fibrin degradation proceeds to completion, plas- 
min is rapidly inactivated by alpha-2 plasmin inhibitor. A 
specific plasminogen activator inhibitor (type I) has been 
identified in human platelets (21) and in the extracellular 
matrix of cultured endothelial cells (22). Recent findings 
underscore the importance of the fibrinolytic system in 
maintaining normal hemostasis and suggest that the balance 
between plasminogen activators and inhibitors may be im- 
portant in both arterial and venous thrombotic disorders. 
Pharmacology of Platelet Inhibitor Drugs 
There has been a continuous interest in the mechanism of 
action of drugs that interfere with platelet function in ath- 
erosclerosis, thrombosis and embolism. Platelet inhibitors 
may exert their effects through several mechanisms includ- 
ing direct inhibition of the arachidonic acid pathway, in- 
crease in platelet cyclic adenosine monophosphate levels 
and inhibition of thrombin formation and action (Fig. 3). 
Inhibitors of the At-achidonic Acid Pathway 
Inhibitors of platelet cyclooxygenase (aspirin). Aspirin and 
other nonsteroidal anti-inflammatory drugs acetylate the 
platelet enzyme cyclooxygenase and, thus, inhibit the for- 
mation of thromboxane A,. Aspirin only partially inhibits 
platelet aggregation induced by adenosine diphosphate, col- 
lagen or thrombin (at low concentrations). The adherence of 
the initial layer of platelets to the subendothelium and the 
release of granule contents are not inhibited by aspirin (23). 
Consequently, the effects of platelet-derived growth factor 
and other mitogens on smooth muscle cell proliferation may 
still occur in the presence of cyclooxygenase inhibitors (24). 
In contrast, these drugs inhibit platelet aggregate formation 
on the layer of adherent platelets, presumably by blocking 
thromboxane A, synthesis. 
The acetylation of cyclooxygenase in platelets exposed to 
aspirin is permanent (25) and, thus, the effects of the drug 
persist for the life of the platelets. The long-term adminis- 
tration of 1 mg/kg per day of aspirin effectively inhibits 
platelet cyclooxygenase and thromboxane A, formation. In 
contrast, aspirin inhibition of vascular endothelial cyclooxy- 
genase is not irreversible because these cells are capable of 
synthesizing new enzyme, though they may require several 
hours to do so. Although earlier studies suggested that 
platelet cyclooxygenase was more sensitive to the inhibitory 
effects of low dose aspirin than was vascular wall cyclooxy- 
genase, more recent experimental data (26) challenge this 
concept. 
The antithrombotic effect of aspirin can be achieved with 
a dose of 160 to 325 mglday and, therefore, the toxic side 
effects associated with higher doses can be avoided (27-29). 
Side effects are dose related and predominantly involve the 
gastrointestinal tract (30). Although higher doses of aspirin 
(>I,000 mgiday) are effective in terms of antithrombotic 
activity, they are associated with substantial gastrointestinal 
toxicity (30,31). For all of these reasons, an aspirin dose of 
160 to 325 mgiday for the prevention of thromboembolic 
disease is currently recommended. Aspirin rarely causes 
significant generalized bleeding unless it is combined with 
anticoagulant therapy. When the risk of thrombosis is high, 
as in unstable angina or during coronary intervention, the 
combination of low dose aspirin (~325 mglday) and an 
anticoagulant is being tested. However, higher doses of 
aspirin can be associated with significant gastrointestinal 
bleeding. 
Although nonsteroidal anti-inflammatory drugs revers- 
ibly inhibit cyclooxygenase, the antithrombotic activity of 
these compounds has not been properly tested in large 
randomized trials and, therefore, their use cannot be recom- 
mended (32). Furthermore, one of the nonsteroidal anti- 
inflammatory agents, indomethacin, has been found to in- 
crease coronary vascular resistance and exacerbate ischemic 
attacks in patients with coronary disease (33). 
Drugs that alter platelet membrane phospholipids (omega-3 
fatty acids). Both eicosapentaenoic acid and docosa- 
hexaenoic acid are present in high concentration in most salt 
water fish, and may account for the lower incidence of 
coronary heart disease in Greenland Eskimos and popula- 
tions that consume large amounts of fish (34,35). Eicosapen- 
taenoic acid competes with arachidonic acid for platelet 
cyclooxygenase. This leads to the formation of two endoper- 
oxidases (prostaglandins G, and H,) and thromboxane A,, 
which have minimal biologic activity (36). Furthermore, 
eicosapentaenoic acid not only does not inhibit endothelial 
prostacyclin production, but also stimulates the formation of 
prostaglandin I,. which has antiplatelet activity (36). The net 
result is a shift in the hemostatic balance toward an antiag- 
gregative and vasodilative state. Docosahexaenoic acid also 
has platelet inhibitory effects and undergoes retroconversion 
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to eicosapentaenoic acid (37). Although fish consumption 
may decrease the incidence of coronary heart disease, fish 
oils are associated with some potentially adverse events 
such as increased bleeding diathesis and reduced inflamma- 
tory and immune responses (37). Before fish oils are recom- 
mended for the prevention of atherosclerosis, properly de- 
signed and controlled human trials are necessary (36). The 
role of fish oils in the prevention of restenosis after coronary 
angioplasty is reviewed later. 
Inhibitors of thromboxane synthetase. Imidazole ana- 
logue thromboxane synthetase inhibitors have been devel- 
oped with the expectation of not only suppressing throm- 
boxane A, biosynthesis, but sparing or even enhancing the 
formation of prostacyclin by the vascular endothelium (38). 
The rationale behind this hypothesis was that, in the pres- 
ence of a thromboxane synthetase inhibitor, platelet-derived 
prostaglandin G, would be transferred to the endothelial 
cells and used in the production of prostacyclin. Although 
thromboxane synthetase inhibitors have shown some bene- 
fits in experimental models (39), their effects in clinical trials 
(40,41) in patients with coronary artery disease have been 
controversial. This may be a result of two factors: 1) 
thromboxane A, may not be completely suppressed by the 
available compounds, and 2) the prostaglandin endoperoxide 
intermediates that result from thromboxane synthetase inhi- 
bition have themselves significant proaggregating effects. 
Blockers of thromboxane and prostaglandin endoperoxide 
receptors. A promising approach to the inhibition of the 
proaggregating and vasoconstrictive effects of thromboxane 
A, is the pharmacologic blockade of the receptors for both 
thromboxane A, and the prostaglandin endoperoxidases 
(42). However, it remains to be demonstrated that such 
agents will offer an advantage over aspirin in suppressing 
thromboxane AZ-dependent platelet function. The combina- 
tion of a thromboxane synthetase inhibitor (which potenti- 
ates prostacyclin synthesis) and a thromboxane A,- 
prostaglandin H, receptor blocker (which prevents the 
proaggregative effect of these compounds) may offer a 
unique approach to platelet inhibition (43) but requires 
further testing. 
Drugs That Increase Platelet Cyclic Adenosine 
Monophosphate Levels 
Dipyridamole. Dipyridamole may increase platelet cyclic 
adenosine monophosphate by three mechanisms: 1) It blocks 
its breakdown by inhibiting phosphodiesterase; 2) it acti- 
vates adenylate cyclase by a prostacyclin-mediated effect on 
the platelet membrane (44); and 3) it increases the levels of 
plasma adenosine by inhibiting its uptake by vascular endo- 
thelium and erythrocytes (45,46). Adenosine, in turn, en- 
hances platelet adenylate cyclase activity. In addition, the 
vasodilative effects of dipyridamole also appear to be related 
to the elevation in plasma adenosine levels. Although there 
are in vitro data to support dipyridamole’s mechanisms of 
action on the platelet, there is no firm clinical evidence that 
such mechanisms contribute to a significant antithrombotic 
effect in humans (46). 
Dipyridamole vs. aspirin. In contrast to aspirin, the 
antithrombotic effects of dipyridamole are more evident on 
prosthetic materials (artificial heart valves [47,48] and arte- 
riovenous cannulas [49]) than on biologic surfaces. Although 
one study (50) showed that aspirin potentiates the efficacy of 
dipyridamole in experimental thromboembolism on pros- 
thetic surfaces, other studies (46) have shown conflicting 
results with regard to the pharmacologic interaction between 
these two agents. Furthermore, aspirin alone was as effec- 
tive as the combination of aspirin and dipyridamole in recent 
antithrombotic trials (51-55) in myocardial infarction, saphe- 
nous vein graft disease and stroke. On the basis of these 
findings, there is little evidence to support the use of 
dipyridamole as an antithrombotic agent except in combina- 
tion with warfarin in high risk patients with a mechanical 
prosthesis (56-60) and possibly in the preoperative period in 
patients with coronary artery bypass surgery (61,62). 
The main side effects of dipyridamole are headache, 
epigastric discomfort and nausea, which occur in >lO% of 
patients but subsequently subside. The agent is not associ- 
ated with gastritis or gastroduodenal ulcers and does not 
increase the bleeding tendency, even when combined with 
an anticoagulant. 
Prostaglandins E, and I,. These prostaglandins are pow- 
erful systemic vasodilators and inhibitors of platelet aggre- 
gation by virtue of their ability to increase platelet cyclic 
adenosine monophosphate. Intravenous infusions of prosta- 
glandin E, are commonly used in neonates with congenital 
heart disease, who are dependent on the persistence of a 
patent ductus arteriosus until surgical correction is done. 
These agents have also been used to improve myocardial 
function in patients with acute myocardial infarction and to 
treat peripheral vascular disease (63). 
Prostacyclin. Prostacyclin is a potent, naturally occur- 
ring platelet inhibitor. Its clinical use has been limited by its 
instability at neutral pH and its propensity to cause signifi- 
cant systemic hypotension at the doses required for platelet 
inhibition. Its duration of action is very short, and the 
pharmacologic effects disappear in 30 min. Infusion of pros- 
tacyclin strongly limits platelet interaction with artificial 
surfaces and preserves platelet number and function during 
cardiopulmonary bypass (64,65). The effects of prostacyclin 
in patients with ischemic heart disease and peripheral 
vascular insufficiency are controversial (63). Emerging 
data, however, suggest that these prostanoids may im- 
prove the results of intracoronary thrombolysis in acute 
myocardial infarction (66,67). Further research in this area is 
needed. 
Prostacyclin analogues. Iloprost, a newly synthetized 
prostacyclin analogue, is chemically stable at neutral pH. In 
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an in vitro comparison with equimolar concentrations of 
prostaglandins I? and E,, iloprost was found to be more 
potent in increasing the levels of platelet cyclic adenosine 
monophosphate and inhibiting platelet aggregation by vari- 
ous agonists, particularly thrombin (68). Another prostacy- 
clin analogue, ciprostene, was found to reduce the rate of 
ischemic events in patients after coronary angioplasty, and 
was associated with a beneficial trend toward a lower rate of 
restenosis (69). Therefore, chemically stable analogues of 
prostacyclin may be effective for temporary control of 
platelet activity in the management of thromboembolic dis- 
orders. These compounds are currently undergoing clinical 
testing. 
Thromhin Inhibitors 
By inhibiting thrombin formation with heparin or oral 
anticoagulant agents, the effects of thrombin on platelets and 
fibrinogen activation can be partially prevented. 
Heparin. Aside from the antithrombotic effects of hep- 
arin, mainly by enhancing antithrombin III activity, the 
effects of this agent on platelet reactions are complex and 
contradictory (70), partly because of the variability among 
different commercially available preparations. There is evi- 
dence that suggests that fractions of high molecular weight 
(approximately 20,000 daltons) are more reactive with plate- 
lets (promoting their aggregation) than are fractions of low 
molecular weight (approximately 7,000 daltons). Therefore, 
antithrombotic therapy may be enhanced by selecting hep- 
arin fractions of low molecular weight and high antithrombin 
III activity. In addition to its antithrombotic effects. high 
dose heparin has inhibitory effects on smooth muscle cell 
proliferation that have been demonstrated experimentally 
(71,72): these effects opens interesting therapeutic opportu- 
nities, particularly with respect to restenosis after coronary 
angioplasty. 
Peptide blockers of thrombin. An alternative strategy 
involves the synthesis of peptides that specifically block 
thrombin-mediated platelet activation (73). A number of 
these agents have been studied in vitro and in experimental 
animals; however, no clinical experience is yet available. 
Another potent selective thrombin inhibitor, hirudin, ini- 
tially isolated from the salivary secretions of the medicinal 
leech, was recently synthesized by deoxyribonucleic acid 
recombinant technology. Hirudin prevents the activation of 
clotting factors V. VIII and XIII; in addition, by being a 
powerful thrombin inhibitor, it blocks the metabolic pathway 
of platelet activation dependent on thrombin. Hirudin was 
recently shown (74) to prevent thrombosis in an animal 
model of carotid angioplasty, and was found to have a more 
potent antithrombotic effect than heparin. Because these 
agents may effectively inhibit platelet activation by blocking 
thrombin, their potential for clinical use is enormous. Inten- 
sive research in this area is currently underway. 
Other Platelet Inhibitors 
Ticlopidine. Ticlopidine is chemically unrelated to other 
antiplatelet drugs; its mechanism of action is not completely 
understood. It may act on the platelet membrane to alter its 
reactivity. perhaps by blocking the interaction of von Wille- 
brand factor and fibrinogen with platelets (75). It inhibits 
platelet aggregation induced by adenosine diphosphate and 
most other agonists, prolongs bleeding time and normalizes 
shortened platelet survival (76). Optimal efficacy is reached 
only after 3 days after its administration, and its effects last 
for several days after administration of the drug has been 
stopped. 
Clinicml evaluation oj’this drug is now underway. Prelim- 
inary evidence from an Italian multicenter trial (77) suggests 
that it is effective in patients with unstable angina for the 
prevention of myocardial infarction and cardiovascular 
death. Another recent study (78) showed a reduction in the 
incidence of acute occlusion and thrombosis after coronary 
angioplasty in patients treated with ticlopidine. In addition, 
this agent was found to be effective in reducing vein graft 
closure in patients after aortocoronary bypass surgery (79). 
Recently published data (80,81) suggest that ticlopidine 
reduces cardiovascular morbidity and mortality in patients 
with stroke, and appears more effective than aspirin in 
patients with transient ischemic attacks. However, ticlopi- 
dine is associated with side effects including rash and neu- 
tropenia. 
Sulfinpyrazone. Sulfinpyrazone is structurally related to 
phenylbutazone but has minimal anti-inflammatory activity. 
In contrast to aspirin, sulfinpyrazone is a competitive inhib- 
itor of platelet cyclooxygenase, but the exact mechanism of 
its antithrombotic activity is not well understood (50). It 
inhibits the formation of thrombus on subendothelium and 
protects the endothelium from chemical injury in vitro and 
possibly in vivo. In addition, sulfinpyrazone produces a 
dose-dependent inhibition of experimental thromboembo- 
lism in artificial cannulas (50) reduces the rate of thrombotic 
events in patients with arteriovenous cannulas (82) and 
normalizes platelet survival in patients with artificial heart 
valves (83). Overall, beneficial effects have been more con- 
sistent on prosthetic than on biologic surfaces. Thus, despite 
a beneficial trend in decreasing vascular events after myo- 
cardial infarction (84) and in reducing the occlusion rates in 
saphenous vein coronary artery grafts (55,85), sulfinpyra- 
zone was found to have no additional benefit in unstable 
angina (31) and stroke (86). Side effects of sulfinpyrazone 
include increased sensitivity to warfarin, hypoglycemia 
when combined with sulfonylureas, exacerbation of peptic 
ulcer and precipitation of uric acid stones. 
Dextran. Dextran of a molecular weight of 65,000 to 
80,000 daltons prolongs the bleeding time after intravenous 
infusion of ~1 liter. Its mechanism of action is unclear. It 
may involve some alteration on platelet membrane function 
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(87) or interference with the factor VIII-von Willebrand 
factor complex (88). Although some experimental studies 
(89) have shown an antithrombotic effect of dextran, no 
effect was found in a randomized trial (90) in patients 
undergoing coronary angioplasty. Furthermore, dextran has 
been associated with a low but disturbing incidence (0.6%) of 
anaphylactoid reactions (91). Data supporting the role of 
dextran as an antithrombotic agent on foreign materials (that 
is, arterial stents and vascular grafts) are emerging. 
Future developments. Currently available drugs do not 
interfere with all the platelet metabolic pathways that lead to 
their activation; therefore, these agents are unable to en- 
tirely prevent thrombus formation. As previously discussed, 
the exposure of receptors in the platelet membrane that bind 
fibrinogen and von Willebrand factor seems to play a pivotal 
role in platelet aggregation (Fig. 2). Therefore, short-term 
total inhibition of platelet aggregation may depend on the use 
of agents such as monoclonal antibodies, which block either 
the fibrinogen receptors on the platelet membrane (92,93) or 
the adhesive macromolecules such as von Willebrand factor 
(94). Similarly, agents that inhibit platelet membrane recep- 
tors responsible for platelet adhesion may be useful for 
short-term therapy. However, long-term therapy may be 
hazardous because of increased bleeding tendency. Finally, 
Table 2. Proposed Model of Sequential Events in Coronary 
Atherosclerotic Disease 
Early lesions (asymptomatic stage) 
Hemodynamic factors: endothelial damage 
Platelet and monocyte deposition 
Smooth muscle cell migration and proliferation 
Connective tissue synthesis 
Lipid transformation and deposition 
Growing lesions (asymptomatic or stable angina stage) 
Slow process 
Chronic endothelial injury 
Platelet and monocyte interaction with vessel wall 
Smooth muscle cell proliferation, collagen synthesis, lipid accumulation 
Rapid process 
Intermittent fissuring of coronary plaques 
Nonocclusive thrombus formation* 
Fibrotic organization of thrombus 
Plaque rupture (acute coronary syndromes) 
Unstable angina 
Plaque rupture with transient thrombosis* 
Vasospasm 
Increased myocardial oxygen demand 
Myocardial infarction 
Plaque rupture with thrombotic occlussion* 
Vasospasm 
Spontaneous recanalization and rethrombosis* 
agents that block the biochemical steps responsible for 
platelet contraction and granular release may play an impor- 
*Events that may be prevented or diminished by use of antithrombotic 
therapy. 
tant role in the inhibition of the processes of platelet secre- 
tion and aggregation and should be investigated. 
occlusive thrombus formation (Table 2). Finally, extensive 
. - 
antithrombotic therapy in different cardiovascular syn- 
dromes, with particular emphasis on the indications for 
platelet inhibitors, based on the results of clinical trials. 
Role of Platelet Inhibitor Agents in 
Cardiovascular Disease 
With a better understanding of the pathogenetic mecha- 
nisms involved in many cardiovascular disorders, the role of 
platelets in thrombosis and thromboembolism has been 
established, and a more extensive role for antithrombotic 
therauv has emerged. We will review the available data on 
Knowledge of the pathogenesis of atherosclerosis, al- 
though still incomplete, is rapidly evolving. The process is 
multifactorial in origin and involves the interaction of genetic 
factors, platelets, smooth muscle cells, endothelium, choles- 
coronary artery disease or myocardial infarction may lead to 
left ventricular dysfunction. The roles of platelets and plate- 
let inhibitors in the asymptomatic phase of coronary athero- 
sclerosis and in the phases of stable angina and acute 
ischemic syndromes will be reviewed. 
Asymptomatic and Stable Angina Phases 
Coronary Atherosclerotic Disease 
The natural history of coronary atherosclerotic disease 
includes a long initial asymptomatic period that lasts three to 
four decades and that may be characterized by benign, 
raised, nonobstructive fatty streaks in the coronary vessels. 
In the presence of a genetic predisposition and certain 
coronary risk factors, these raised plaques grow and either 
remain silent or produce clinical symptoms of angina pecto- 
ris. The acute coronary syndromes, namely, unstable an- 
gina, myocardial infarction and ischemic sudden death, may 
occur when growing plaques undergo a rapid morphologic 
change after they rupture, with significant occlusive or near 
terol and lipoproteins. 
Slow progression of atherosclerosis. Platelet deposition in 
areas of subtle endothelial injury may constitute one of the 
initiating factors in the development of atheromatous plaque. 
Areas of increased turbulence such as branching points are 
particularly susceptible to endothelial injury. Through the 
interaction of von Willebrand factor, collagen, fibronectin 
and other proteins, platelets become firmly attached to gaps 
between endothelial cells or to injured vascular wall, and 
may release several mitogens including platelet-derived 
growth factor, epidermal growth factor and transforming 
growth factor beta. These factors stimulate the proliferation 
and migration of smooth muscle cells and fibroblasts from 
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the media to the intima of the vessel wall. Platelet interaction tion only to individuals at high risk for coronary artery 
with injured endothelium may induce a rapid proliferative disease, in whom the benefits of therapy outweigh its risks. 
response, whereas other sources of growth factors including Further analysis (98a) of the United States Physicians’ 
activated macrophages and endothelial cells may be respon- Health Study (97) suggests that aspirin exerts a greater 
sible for stimulating smooth muscle cells at a slower rate and impact on patients at higher risk for coronary events, namely 
producing atherosclerosis even in the absence of endothelial those with cardiovascular risk factors or evidence of cere- 
disruption (95). bral or peripheral vascular disease. 
In the experimental hyperlipidemic model of atheroscle- 
rosis (95), monocytes attach to the endothelium early after 
the induction of hypercholesterolemia. These monocytes 
then localize subendothehally, accumulate lipid and become 
foam cells, which eventually constitute fatty streaks. After 
several months. the endothelium that covers the fatty 
streaks retracts and allows the attachment of platelets to 
areas of endothelial desquamation or to the subendothelium 
(95). All principal cells involved in the atherosclerotic pro- 
cess-endothelium, platelets, monocytes and smooth mus- 
cle cells-are capable of releasing chemotactic and mitogen- 
ic factors. In hyperlipidemia, interaction of monocytes with 
the vessel wall and monocyte-dependent growth factor or 
factors may be more important than platelet-dependent 
factors. 
lf plutelet adherence to the vessel wall plays a role in 
utherogenesis, then inhibition of platelet adhesion may be 
beneficial in preventing atherosclerosis. Unfortunately, no 
drug with this property is currently available. If platelet 
adhesion were to be completely prevented by a pharmaco- 
logic agent, as occurs in pigs with an absence or alteration of 
von Willebrand factor (96), the risk of bleeding would 
prohibit its long-term use. In contrast, such an agent may 
prove beneficial when short-term inhibition of platelet adhe- 
sion is desired (such as during coronary angioplasty or after 
coronary thrombolysis). 
Progression of atherosclerosis. Rupture of small athero- 
sclerotic plaques, with subsequent mural thrombosis and 
fibrotic organization of thrombus, may contribute to the 
progression of coronary atherosclerosis. This concept is 
based on the pathologic finding of old, organized coronary 
thrombi difficult to distinguish from atherosclerotic changes 
seen in the arterial wail (99). A more recent study (100) 
demonstrated the presence of fibrinogen, fibrin and their 
degradation products in areas of advanced atherosclerotic 
plaques. On the basis of these observations, recurrent epi- 
sodes of plaque disruption and thrombosis may lead not 
necessarily to acute ischemic syndromes, but to progressive 
narrowing of the coronary arteries. Although it is as yet 
unknown how prevalent this process is, its clinical signifi- 
cance is potentially enormous because thrombotic episodes 
may be prevented by platelet inhibitors or anticoagulant 
agents. In this context, a 5 year trial of platelet inhibitor 
therapy in the angiographic progression of coronary disease 
in patients with stable angina was recently completed at the 
Mayo Clinic. Preliminary evidence suggests that platelet 
inhibitors reduce the incidence of myocardial infarction and 
new lesion formation (lOOa). 
Acute Coronury Syndromes 
Primary prevention. Results from a double-blind, pla- 
cebocontrolled trial (97) of >22,000 male physicians in the 
United States assigned to receive aspirin (325 mg every other 
day) for 5 years revealed a 44% reduction in the incidence of 
myocardial infarction from approximately 0.4% to 0.2% per 
year (p < 0.00001). Before advising the widespread use of 
aspirin in apparently healthy people, three issues need to be 
considered. First, there was a slight increase in the incidence 
of hemorrhagic stroke in the aspirin-treated group. Second, 
in a randomized British primary prevention trial (98) that 
involved >5,000 male physicians, the use of aspirin (500 
mg/day) did not reduce the rate of myocardial infarction, but 
did increase the incidence of disabling stroke. Third, the 
long-term effects of aspirin blockade of the prostaglandin 
system in various tissues. particularly the central nervous 
system, are unknown. 
Angiographic (101,102), angioscopic (103) and pathologic 
(104.105) studies have demonstrated the presence of com- 
plex ulcerated plaques with or without thrombus formation 
in a large proportion of patients with unstable angina, 
myocardial infarction or ischemic sudden death. The causes 
of plaque rupture are unknown, but may be related to the 
physicochemical properties of the plaque (fragility of the 
fibrous cap, infiltration by foam cells, abnormal elastin), 
hemodynamic factors (wall shear stress, changes in vasoto- 
nicity and blood pressure) and continuous arterial bending 
and twisting with each cardiac cycle. Plaque rupture exposes 
collagen fibrils and tissue thromboplastin, promoting the 
development of thrombus. The degree, suddenness and 
duration of the obstruction and size of the involved vessel 
probably determine the nature of the clinical event. 
Increase in hemorrhagic stroke. Even though these stud- 
ies were done in healthy volunteers and, admittedly, their 
conclusions should be applied only to “healthy individuals,” 
the increased incidence of hemorrhagic stroke is disconcert- 
ing. Therefore, we recommend aspirin for primary preven- 
Unstable angina (Table 3). Plaque disruption in areas of 
mild coronary stenosis may lead to an acute change in plaque 
morphology and a reduction in coronary blood flow, result- 
ing in progressive ischemic symptoms. Transient episodes of 
thrombotic vessel occlusion at the site of injury may occur, 
resulting in rest angina (103). Additionally, blood supply may 
be further compromised by intermittent vasoconstriction 
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Table 3. Reported Results of Antithrombotic Therapy in Unstable Angina 
No. of 
Reduction in Event Rate (%) 
Trial (reference) Patients Follow-up Drug Mortality Cardiac Death t MI 
Telford and Wilson (108) 214 7 days Heparin - 80* 
VACS (27) 1,216 12 weeks Aspirin 51 51t 
Cairns et al. (31) 555 18 months Aspirin 718 51P 
Sulfinpyrazone 9 (-6) 
Theroux et al (107) 479 6 days Aspirin - 728 
Heparin - 89t 
STAI (77) 652 6 months Ticlopidine 57 531 
*p < 0.05; tp < 0.001; Sp < 0.005; §p < 0.01. MI = myocardial infarction; STAI = Study ofTiclopidine in Unstable Angina; VACS = Veterans Administration 
Cooperative Study. 
related to the release of vasoactive substances from platelets 
or to a deficiency of endothelium-derived relaxing factor in 
areas of atherosclerosis (106). Alternatively, transient in- 
creases in myocardial oxygen demand may explain some of 
the episodes of unstable angina. 
Aspirin therapy. There have been three large, random- 
ized, placebo-controlled, double-blind studies of aspirin in 
unstable angina. In the Veterans Administration Coopera- 
tive Study (27), 1,266 men with unstable angina were ran- 
domized to buffered aspirin (324 mg/day) or placebo for 12 
weeks. During the treatment period, the incidence of death 
and acute myocardial infarction was reduced from 10.1% to 
5.0% in the treated group (p = 0.0005). More importantly, 
the overall benefits of aspirin were maintained in the 1 year 
follow-up period. No increase in gastrointestinal side effects 
was seen in the aspirin-treated group. In the Canadian 
Multicenter Trial (3 I), 555 patients (73% men) with unstable 
angina were randomized to receive aspirin (1,300 mg/day), 
sulfinpyrazone (800 mg/day), the combination of both, or 
placebo. After 2 years, the incidence of death and myocar- 
dial infarction was reduced in the aspirin-treated groups 
from 17% to 8.6%, a risk reduction of 51% (p = 0.008) (Fig. 
4). Sulfinpyrazone conferred no benefit and did not interact 
with aspirin. Gastrointestinal toxicity was more frequently 
Figure 4. Efficacy of aspirin versus no aspirin in reducing cardiac 
death or nonfatal myocardial infarction in patients with unstable 
angina. Continuous line indicates aspirin-treated patients; dotted line 
indicates patients who did not receive aspirin. Reproduced with 
permission from N Engl J Med (31). 
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seen in the aspirin-treated groups, probably related to the 
high dose used. 
In the recently published Montreal Heart Institute Study 
(107), 479 patients with unstable angina were randomized to 
aspirin (325 mg twice daily), intravenous heparin, the com- 
bination of both, or placebo. The study was ended after a 
mean of 6 days when a final therapeutic decision for the 
individual patient was made. Aspirin significantly reduced 
rate of myocardial infarction by 72% compared with pla- 
cebo. Further support for the use of antiplatelet agents in 
unstable angina comes from the recently completed Italian 
Study of Ticlopidine in Unstable Angina (S.T.A.I.) (77). 
Preliminary evidence from this study showed that ticlopidine 
at a dose of 250 mg twice daily for 6 months reduced the 
incidence of mortality and myocardial infarction by >50%. 
Anticoagulant therapy. Evidence of a beneficial effect of 
heparin in unstable angina was suggested by Telford and 
Wilson (108), who demonstrated an 80% reduction in the 
incidence of myocardial infarction in patients with unstable 
angina treated with heparin for 7 days. Deficiencies in 
patient recruitment, however, left the conclusions of this 
study less convincing. The strongest support for immediate 
anticoagulation in unstable angina comes from the Montreal 
Heart Institute Study (107). Heparin decreased the rate of 
infarction by 89% and the incidence of refractory angina by 
50%. Although no statistically significant difference among 
aspirin, heparin or their combination was found, there was a 
trend favoring heparin over aspirin. The combination was 
associated with a slight increase in bleeding complications. 
This study confirms the concept that an aggressive an- 
tithrombotic approach to patients with unstable angina is 
beneficial. A multicenter randomized trial of anticoagulants 
plus low dose aspirin in unstable angina is currently under- 
way. 
Non-Q wave infarction. The angiographic configuration 
of the responsible lesion in non-Q wave infarction is similar 
to that seen in unstable angina (109), which suggests that 
plaque disruption is common in both syndromes. The pres- 
ence of ST segment elevation on the electrocardiogram 
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(ECG) (1 lo), early peak in plasma creatine kinase (1 IO, I1 1) 
and high angiographic patency rates of the infarct-related 
artery (110-l 12) suggest that complete coronary occlusion 
followed by early reperfusion is important in the pathogen- 
esis of non-Q wave infarction. Reperfusion may occur as a 
result of spontaneous thrombolysis or resolution of vaso- 
spasm. or both. Furthermore, contraction band necrosis, 
which is the hallmark of reperfusion, is more often found in 
patients dying of non-Q wave versus Q wave infarction 
(113). In contrast, when complete coronary occlusion is 
persistent, the presence of adequate collateral flow may limit 
the extent of myocardial necrosis and prevent the develop- 
ment of a Q wave infarction (112). Given the high incidence 
of reinfarction and vascular death in these patients, not 
unlike those with unstable angina, aggressive antithrombotic 
therapy may be beneficial. This hypothesis requires clinical 
testing. 
Q wave infarction. In Q wave infarction, atherosclerotic 
plaque rupture leads to fixed and persistent occlusive throm- 
bus formation (104). Quantitative angiographic studies ( 114) 
have shown that the coronary lesion responsible for the 
infarction may be only mild to moderately stenotic. This 
suggests that plaque rupture with thrombus formation, 
rather than the severity of the underlying stenosis (114-l 16), 
may be the primary determinant of acute occlusion. Myo- 
cardial infarction may also be favored by alterations in- 
hemostasis, such as increased activation of the coagulation 
system, increased platelet aggregability, elevated fibrinogen, 
increased factor VII activity or deficient fibrinolytic mecha- 
nisms (117,118). 
Platelet inhibitor therapy. The strongest evidence sup- 
porting the use of platelet inhibitors in the acute stage of 
myocardial infarction comes from the recently published 
Second International Study of Infarct Survival (ISIS-2) (29). 
In this study, >17,000 patients with suspected acute myo- 
cardial infarction were randomized to aspirin (160 mg/day), 
intravenous streptokinase, both or placebo. At 5 weeks, the 
vascular mortality rate was significantly reduced by aspirin 
alone (by 23%), streptokinase alone (by 25%) and the com- 
bination of both (by 42%). Because a certain number of 
patients with acute infarction undergo spontaneous or chem- 
ically induced vessel recanalization, aspirin probably owes 
its beneficial effects to a reduction in early reinfarction. 
Indeed, aspirin decreased the rate of nonfatal reinfarction by 
50% in this study (29). It should be noted that because 
admission into this trial did not require ECG confirmation of 
acute infarction, some patients probably had unstable an- 
gina, a situation for which aspirin has clearly proved to be 
beneficial (27,31,107). 
Anticoagulant therapy. Although the purpose of this 
review is to analyze the value of platelet inhibitor therapy in 
cardiovascular disease, it is important to mention briefly the 
results obtained with the use of anticoagulants. The role of 
anticoagulants in patients with acute infarction for the pre- 
vention of coronary rethrombosis, infarct extension and 
death has not been settled. Of the large number of studies 
conducted, only three randomized trials (I 19-121) have been 
sufficiently large to be able to detect a significant effect of 
therapy. Although all three studies showed a beneficial trend 
toward reduced incidence of death and reinfarction, only the 
Bronx Municipal Hospital trial (120) found a significant 
reduction (30%) in the case fatality rate. In addition, antico- 
agulant therapy has been clearly shown to reduce pulmonary 
and systemic embolism after myocardial infarction (119-121) 
and the incidence of left ventricular mural thrombosis in 
cases of acute anterior infarction (122). Therefore, it appears 
that in patients with acute myocardial infarction, both aspi- 
rin and short-term anticoagulant therapy are associated with 
lower incidence of death and reinfarction (29,123). 
Secondury Prevention After Myocurdial 
InjkircTion 
Antiplatelet therapy (Table 4). With respect to the use of 
antiplatelet agents for secondary prevention of vascular 
events, several large, randomized, placebo-controlled, dou- 
ble-blind trials (5 I ,84,124-130) in postmyocardial infarction 
patients have been conducted. In seven of these trials, 
aspirin (at a dose of 300 to 1,500 mgiday) was used alone or 
combined with dipyridamole. In the remaining two trials, 
sulfinpyrazone was used. Despite the large total number of 
patients studied (>17,000), no clear evidence of benefit from 
therapy was shown in any single study. Reduction in cardiac 
mortality rate varied from 5% to 42%, and in nonfatal 
reinfarction rate from 12% to 57% (Table 4). The largest 
single trial, the Aspirin Myocardial Infarction Study (128), 
showed no benefit from therapy, but unbalanced randomiza- 
tion introduced an inadvertent bias against aspirin. The rest 
of the trials disclosed a beneficial trend from therapy in 
terms of lower mortality rate and, in some cases, a signifi- 
cant reduction in coronary event rate (84,127,130). 
A pooled analysis of antiplatelet therapy in secondary 
prevention after myocardial infarction was recently pub- 
lished in the British Medical Journul (13 1). It suggests that, 
in survivors of myocardial infarction, platelet inhibitors 
significantly reduce the vascular mortality rate by 13%, 
nonfatal reinfarction rate by 3 1% and nonfatal stroke rate by 
42% without any effect on the nonvascular mortality rate. 
Although no statistically significant differences among the 
antiplatelet agents used were found, current evidence does 
not justify the additional expense and increased frequency of 
administration of dipyridamole or sulfinpyrazone (46,13 I). 
At present, the best studied, most convenient and least 
expensive antiplatelet drug appears to be aspirin at a dose no 
greater than 325 mg/day. 
Anticoagulant therapy. Numerous studies have assessed 
the usefulness of long-term anticoagulation in the secondary 
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Table 4. Randomized Trials of Platelet Inhibitors for Secondary Prevention of Myocardial Infarction 
Reduction in Event Rate With Therapy (%) 
No. of Total Cardiac Coronary 
Trial (reference) Patients Drug (mg day) Mortality Mortality Events 
MRC-I (124) 1.239 Aspirin (300) 24 NA NA 
CDP (125) 1,529 Aspirin (972) 30 28 22 
GARS (126) 626 Aspirin (1,500) I8 42 37 
MRC-II (127) 1,682 Aspirin (900) 17 22 2g* 
AMIS (128) 4,524 Aspirin (1,000) (- 10) C-8) 5 
PARIS-I (51) 2,206 Aspirin (972) 18 21 24 
Aspirin (972) t dipyridamole (225) 16 24 25 
ART (129) 1,558 Sulfmpyrazone (800) 2gt 24t NA 
ARKS (84) 727 Sulfinpyrazone (800) 5 5 563: 
PARIS-II (130) 3,128 Aspirin (990) t dipyridamole (225) 3 6 24* 
*p < 0.05; tLower total and cardiac mortality are due to a marked reduction in early sudden death. Sp < 0.01. 
AMIS = Aspirin Myocardial Infarction Study; ARIS = Anturane Reinfarction Italian Study; ART = Anturane Reinfarction Trial; CDP = Coronary Drug 
Project; CARS = German-Austrian Reinfarction Study; MRC-I = Medical Research Council (1974); MRC-II = Medical Research Council (1979); NA = Not 
available; PARIS-I = Persantine-Aspirin Reinfarction Study (1980); PARIS-II = Persantine-Aspirin Reinfarction Study (1986). 
prevention of cardiovascular disease after myocardial infarc- 
tion, but only four randomized controlled trials (126,132- 
134) were large enough to be able to detect a significant effect 
from therapy. Three of these studies (126,132,133) random- 
ized patients soon after infarction and followed their course 
for several years. Although no significant reduction in the 
mortality rate was seen in any of the trials, anticoagulant 
therapy reduced the reinfarction rate by 60% in the Medical 
Research Council Study (132). Utilizing a different design, 
the Sixty Plus Reinfarction Study (134) entered patients >60 
years of age who had been maintained on anticoagulant 
therapy for a median of 6 years after infarction. Patients 
were randomized to continuation of anticoagulant therapy or 
to placebo substitute. At the end of 2 years, patients taking 
anticoagulants had a 26% lower death rate (p = 0.07) and an 
impressive 55% reduction in the incidence of reinfarction 
(p = 0.0005). The recently completed large Warfarin Rein- 
farction Study (WARIS), which is awaiting publication, will 
help to define the role of anticoagulant’s after myocardial 
infarction. 
The French E.P.S.I.M. (Enquete de Prevention Secon- 
daire de 1’Infarctus du Myocarde) trial (135) attempted to 
compare anticoagulant therapy with aspirin in postinfarction 
patients; however, no controlled group was included. At 
29 months of follow-up, no significant difference between 
the two treatment arms emerged with regard to total and 
cardiac mortality and reinfarction rates. When the trials 
of aspirin and anticoagulants for secondary prevention 
of cardiac disease are analyzed together, both treatments 
appear to convey some protection against death and 
reinfarction; however, long-term anticoagulant therapy 
is costly and is associated with a significant risk of 
bleeding. 
Current Recommendations 
1) The preferred platelet inhibitor drug in patients with 
unstable angina is aspirin at a dose of 325 mglday, and its 
beneficial effect is still present in the 2 year follow-up period. 
In addition, a recent trial (107) suggests that high dose 
anticoagulant therapy with heparin significantly reduces the 
incidence of infarction and refractory angina in these pa- 
tients. The short-term combination of aspirin (80 mglday) 
and low dose warfarin is currently being evaluated. 
2) Recent evidence suggests that aspirin (160 mglday) is 
beneficial in patients with acute myocardial infarction by 
reducing reinfarction, stroke and early cardiovascular death 
(29). Short-term administration of anticoagulants may also 
be beneficial in reducing the incidence of reinfarction and 
death, although the available data are still controversial. 
Anticoagulants are particularly effective in reducing left 
ventricular mural thrombosis and systemic embolism in 
patients with anterior myocardial infarction. 
3) For secondary prevention in survivors of myocardial 
infarction, aspirin therapy reduces the incidence of vascular 
mortality, reinfarction and stroke. Although daily doses 
ranging from 300 to 1,500 mg have been used, the lower 
dosage is as effective as the larger one, but produces fewer 
side effects. Available data do not support the use of 
sulfinpyrazone or dipyridamole. Long-term anticoagulant 
therapy is also beneficial in reducing reinfarction, but is 
associated with significant cost, patient discomfort and hem- 
orrhagic side effects. 
4) Patients with stable coronary disease or stable angina 
are commonly treated with aspirin, although its beneficial 
effects need confirmation by ongoing clinical trials. 
5) Aspirin for primary prevention is still controversial. At 
present, it may be recommended only to individuals at high 
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risk of developing significant coronary disease, in whom the 
potential benefits of aspirin outweigh its risks, such as those 
with hemorrhagic stroke. 
Saphenous Vein Bypass Graft Disease 
Coronary vein graft disease is the most important con- 
tributor to cardiac morbidity and mortality after coronary 
artery surgery. Occlusion rates are 8% to 18% per distal 
anastomosis at 1 month postoperatively and 16% to 26% at 
12 months (136). At the end of 10 years, up to 50% of vein 
grafts will be occluded. Vein graft disease can be divided 
into two main phases: an early postoperative phase of 
thrombotic occlusion, and a late phase composed of intimal 
hyperplasia due to smooth muscle cell proliferation, occlu- 
sive and nonocclusive graft thrombosis and atherosclerotic 
plaque formation (137). The late phase of vein graft disease 
probably represents a continuum of the hyperplastic re- 
sponse to injury with superimposed thrombotic tendency, 
which may develop at any point during the disease process. 
Early Phase of Vein Graft Disease 
The initial endothelial damage to a saphenous vein graft 
occurs when the vein is removed from the leg during surgery 
and is suddenly exposed to the high pressure arterial system. 
Saphenous vein endothelium is injured during harvesting 
from the leg, surgical handling and suturing and immediately 
after anastomosis when the vein is abruptly exposed to 
arterial shear forces (137,138). As blood starts to flow 
through the graft, platelets, activated after passing through 
the extracorporeal oxygenator, adhere to areas of damaged 
endothelium and release their thromobogenic factors. With 
the understanding that early vein graft occlusion is mainly 
thrombotic in origin and platelet deposition begins intraop- 
eratively (139), platelet inhibitor drugs are indicated for the 
prevention of early graft occlusion, and this therapy should 
be started before or immediately after surgery. 
Dipyridamole and aspirin. Several studies (54,55,61,62, 
140-142) have convincingly demonstrated the importance of 
initiating platelet inhibitor therapy in the perioperative pe- 
riod, preferably before but no later than 48 h after surgery. 
Indeed, when therapy was started >48 h after surgery, no 
reduction in the vein graft occlusion rate was observed 
(143-146). Experimentally, preoperative treatment with 
dipyridamole appears to decrease platelet activation by the 
extracorporeal pump, maintains the platelet count during 
cardiopulmonary bypass, and does not increase bleeding 
during surgery (139,147). Accordingly, in a randomized, 
double-blind, placebo-controlled trial (61), patients received 
dipyridamole (100 mg four times daily) for 2 days preopera- 
tively, followed by aspirin (325 mg) and dipyridamole (75 
mg) three times daily, started 7 hours postoperatively and 
continued for 1 year. There was no increased incidence of 
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Figure 5. Occlusion rates for all types of vein grafts are shown per 
distal anastomosis and per patient. Occlusion rates are shown within 
1 month, new occlusions beyond 1 month and late after operation 
(median 1 year). Below each percentage, the ratio of occlusion to the 
total number of distal anastomoses and the ratio of the number of 
patients with occlusion to the total number of patients is shown. 
Solid bars depict treated groups; dotted bars depict placebo groups. 
Reproduced with permission from N Engl J Med (62). 
bleeding complications in the treatment group. At vein graft 
angiography 1 month postoperatively, there was a significant 
reduction in the incidence of graft occlusion in the treated 
group from 10% to 2% per distal graft anastomosis and from 
22% to 6% per patient (Fig. 5). This was true even in patients 
at high risk for early graft occlusion. 
Other antiplatelet agents. In another study (79), ticlopi- 
dine (250 mg twice daily) started on the second postoperative 
day significantly reduced the incidence of vein graft occlu- 
sion as assessed angiographically at 10, 180 and 360 days 
after surgery. In the recently published Veterans Adminis- 
tration Cooperative Study (55), 555 patients were random- 
ized into five groups: aspirin (325 mgiday), aspirin (325 mg 
three times a day), aspirin (325 mg) plus dipyridamole (75 
mg) three times a day, sulfinpyrazone (267 mg three times a 
day) and placebo. Except for aspirin, which was started 12 h 
preoperatively, therapy was initiated 48 h before surgery. 
Graft patency was assessed angiographically between 6 and 
60 days (median 9) after surgery. The early graft patency rate 
was significantly higher in the aspirin treatment groups (92% 
to 93.5%) as compared with placebo (85%). There was a 
nonstatistically significant trend toward an improved pa- 
tency rate with sulfinpyrazone, but this therapy was associ- 
ated with transient renal insufficiency in 5% of patients. It is 
important to note that one daily dose of aspirin was as 
effective as aspirin given three times a day, and that dipyr- 
idamole conferred no additional benefit over aspirin alone. 
Because aspirin was given preoperatively, bleeding during 
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and after surgery, transfusion requirements and reoperation 
rate were significantly greater in the aspirin-treated patients 
(55). 
Late Phase of Vein Graft Disease 
Pathogenesis. This phase probably represents a contin- 
uum of the pathologic process that affects vein grafts when 
exposed to the arterial circulation. Its pathogenesis is most 
likely multifactorial. As stated before, platelet deposition in 
areas of endothelial damage occurs as soon as the graft is 
exposed to arterial shear forces (147,148). Smooth muscle 
cell proliferation leading to intimal hyperplasia may follow 
(138,149), probably as a result of chronic endothelial injury 
and release of mitogenic factors from platelets or perhaps 
other cells. Occlusive or nonocclusive thrombus formation 
may occur at any point during the disease process, as 
documented in surgical specimens (150), autopsy studies 
(137,138,149) and experimental models (139). Finally, 
months to years after graft implantation, intimal fibrous 
plaques consisting of smooth muscle cells, foam cells, col- 
lagen and foci of calcification develop (137,149). These 
fibrous plaques are indistinguishable from atherosclerotic 
plaques that occur in the native coronary arteries. 
In a recent study (150) two-thirds of vein grafts removed 
during a second coronary artery bypass operation showed 
evidence of mural or occlusive thrombosis. This was partic- 
ularly prevalent in atherosclerotic grafts and those with 
aneurysmal dilation, which suggests that late thrombosis is 
not an uncommon event in chronically injured grafts. 
Prevention. The available platelet inhibitors do not pre- 
vent platelet adherence to the injured endothelium or the 
release of their mitogenic factors. Thus, smooth muscle cell 
proliferation and intimal hyperplasia are not affected by 
these drugs (136). In contrast, antiplatelet agents have been 
beneficial in reducing the rates of early and late (up to 1 year) 
vein graft occlusion (62,79). This benefit is most likely a 
result of the effect of these drugs in limiting superimposed 
thrombus formation, rather than through a direct effect on 
the primary occlusive proliferative process. No currently 
available agent prevents graft atherosclerosis, although con- 
trol of risk factors such as hyperlipidemia and cigarette 
smoking may be beneficial (150). In a new trial sponsored by 
the National Institutes of Health on the prevention of vein 
graft atherosclerosis, the use of aspirin and lipid-lowering 
therapy, either alone or in combination, will be tested. 
Current Recommendations 
1) For the prevention of early thrombotic occlusion of 
saphenous vein bypass grafts, platelet inhibitor therapy 
appears to be mandatory. Because preoperative aspirin is 
associated with increased intraoperative bleeding (55), we 
recommend the use of dipyridamole preoperatively (which 
prevents activation of platelets by the extracorporeal pump 
and does not increase bleeding) (61), but we realize that its 
benefit needs clinical proof. Most importantly, aspirin alone 
(at a dose of 325 mglday) should be started immediately after 
surgery and continued for at least 1 year. Postoperative 
dipyridamole confers no additional benefit to that of aspirin 
alone (55). 
2) It is not yet clear whether aspirin should be continued 
indefinitely. However, on the basis of previously reviewed 
available data on native coronary disease, long-term aspirin 
use for the prevention of coronary artery or graft thrombotic 
disease is perhaps justified. 
3) The control of coronary risk factors is essential. After 
the first postoperative year, vein graft atherosclerotic dis- 
ease is conditioned by the risk factors predisposing to native 
coronary disease. 
Postangioplasty Occlusion and Restenosis 
Percutaneous transluminal coronary angioplasty is an 
important alternative to surgical revascularization in suitable 
patients with coronary artery disease, and its use has been 
greatly expanded in the last few years. Fracture or splitting 
of the stenotic lesion, medial disruption and stretching or 
expansion of the external diameter of the artery are probably 
necessary for successful angioplasty (15 1,152). Endothelial 
denudation, platelet deposition and mural thrombus forma- 
tion occur immediately after angioplasty and may lead to 
acute occlusion and restenosis (153). 
Acute Occlusion 
The pathogenesis of acute occlusion probably involves 
one or several mechanisms including formation of large 
folded intimal flaps as a result of intimal-medial dissection; 
arterial damage associated with residual stenosis, which 
facilitates platelet and clotting activation and thrombosis: 
vasospasm or relaxation of overstretched vessel wall seg- 
ments, or subintimal plaque hemorrhage, especially after 
thrombolytic therapy (154). Experimental angioplasty in 
animals has shown that when arterial injury is mild, it is 
associated with endothelial denudation and subintimal dep- 
osition of platelets. In contrast, extensive arterial wall dam- 
age or dissection leads to exposure of media and collagen, 
which are profoundly thrombogenic despite systemic hepa- 
rinization (153). 
Prevention. With regard to preventive therapy for acute 
occlusion after coronary angioplasty, recent studies strongly 
suggest that pretreatment with platelet inhibitors such as 
aspirin alone (155), aspirin plus dipyridamole (78,155,156) or 
ticlopidine (78) significantly reduces the incidence of acute 
thrombotic occlusion and periprocedural Q wave infarction. 
A recent prospective study (157) indicated that aspirin alone 
was as effective as the combination of aspirin and dipyri- 
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damole. Although the use of heparin in the prevention of 
occlusion has not been tested in randomized trials, data 
derived from uncontrolled trials (158,159) in patients with 
unstable angina indicate that pretreatment with heparin 
reduces acute thrombotic complications after angioplasty. 
Furthermore, there is experimental evidence (160) support- 
ing the use of adequate doses of heparin in the prevention of 
thrombus formation, 
Late Restenosis 
Restenosis is the major complication after successful 
angioplasty, with an incidence of 25% to 30%. Although its 
definition varies among investigators, a number of clinical, 
anatomic and procedural variables that predispose to rest- 
enosis have been found (161,162). Factors associated with a 
higher restenosis rate include recent onset or crescendo or 
unstable angina, diabetes mellitus, the presence of a severe 
preangioplasty stenosis (163), proximal as opposed to distal 
dilations, lesions in the left anterior descending coronary 
artery (164), dilation of multiple lesions in the same vessel 
(165) a high postangioplasty residual stenosis (163,166) and 
severe vessel injury, with large and complicated intimal 
dissection (166). 
The pathogenesis of restenosis is not entirely understood 
and may involve several different mechanisms. Increased 
residual luminal stenosis after dilation produces a high local 
shear rate and favors platelet deposition and thrombosis 
(161). Deep arterial injury, with subsequent exposure of 
librillar collagen and release of tissue thromboplastin, favors 
platelet aggregation, activation of the coagulation system 
and thrombus formation (153,167). Furthermore, vascular 
injury may lead to the release of growth factors from any of 
four sources: platelets, smooth muscle cells, endothelium 
and macrophages (95). These growth factors are potent 
mitogens for smooth muscle cells and fibroblasts. When this 
proliferative response is excessive, large amounts of connec- 
tive tissue matrix can be formed, resulting in intimal hyper- 
plasia and recurrent arterial stenosis (153). Finally, the 
release of vasoactive substances by aggregating platelets 
(168) loss of endothelium-derived relaxing factor as a con- 
sequence of endothelial damage (106) and alteration in the 
prostaglandin metabolism (169) may result in vasoconstric- 
tion and potentially contribute to restenosis. 
Antithromhotic agents. Factors important in reducing the 
incidence of restenosis include a technically successful an- 
gioplasty, which reduces platelet deposition by limiting the 
shear rate, and adequate antithrombotic therapy, ideally 
started before the procedure, to reduce the hemostatic 
response to arterial wall injury. Unfortunately, results of 
clinical trials using different antiplatelet drugs and anticoag- 
ulant agents aimed at reducing the restenosis rate have been 
disappointing. In recent clinical studies, aspirin plus dipy- 
ridamole (156,170) or ticlopidine (170) failed to reduce the 
rate of restenosis. Similarly, anticoagulation with Coumadin 
(crystalline warfarin sodium) for 6 months was of no benefit 
compared with aspirin (171). Other unsuccessful attempts 
aimed at reducing restenosis rates have included administra- 
tion of high dose steroids (172,173) and calcium channel 
blockers (174.175). 
Omega-3 fatty acids. The use of omega-3 fatty acids in 
postangioplasty patients has generated a great deal of inter- 
est, but available studies (176-180) have yielded conflicting 
results. The most carefully conducted of these studies (176) 
found a significant reduction in restenosis rate, as assessed 
angiographically. In this trial, fish oils were initiated 7 days 
before angioplasty, and the effects of therapy on platelet 
fatty acid concentration were evaluated. Two other trials 
(177.178), using mostly nonangiographic definitions of reste- 
nosis, also found benefit from fish oil therapy. The other two 
studies (179,180) that employed angiographic follow-up eval- 
uations found no benefit from therapy. Although no definite 
recommendations can currently be made given available 
conflicting data, there is evidence to suggest that pretreat- 
ment with large doses of omega-3 fatty acids is beneficial in 
selected patients. 
Long-term heparin. Heparin has been shown to supress 
smooth muscle cell proliferation in an animal model of 
vascular injury (71) and in vitro cell culture (72); however, 
adequate clinical trials of long-term heparin in postangio- 
plasty patients are lacking. A recent study (181) compared 
short-term heparin (given for 18 to 24 h) versus placebo after 
angioplasty. and found no difference in restenosis rate at 6 
months. Long-term subcutaneous heparin therapy after an- 
gioplasty has not been properly tested in humans. 
Coronary stents. Recent evidence (182) suggests that 
mechanical devices such as intracoronary stents may pre- 
vent acute vessel closure and, perhaps, reduce the incidence 
of restenosis in selected patients. Because these results are 
still preliminary and acute thrombotic occlusion has compli- 
cated some of these cases, the widespread use of these 
devices awaits large scale clinical trials. 
Current Recommendations. 
1) Until the results of ongoing and future clinical trials 
are available, the best empiric antithrombotic therapy for 
the prevention of acute occlusion may be aspirin, started 1 
day before angioplasty, followed by a dose of 325 mg 1 h 
before the procedure and daily thereafter. 
2) All patients should receive a bolus of heparin (100 
Ulkg) at the beginning of the procedure, followed by an 
intravenous infusion (at approximately 15 U/kg per h), which 
should be continued for several hours; the length of heparin 
therapy will depend on whether a thrombus or a large vessel 
wall dissection is detected at the end of the procedure. 
3) Antiplatelet therapy reduces the incidence of acute 
occlusion. but its effect on late restenosis is doubtful. A 
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Table 5. Randomized Trials of Platelet Inhibitors Added to Anticoagulant Therapy in Mechanical Prosthetic Valves 
Study (reference) Therapy No. of Patients Embolic Events (%) Results of Added Therapy 
Sullivan et al. (56) 
Altman et al. (189) 
Dale et al. (190) 
Kasahara (57) 
Groupe de Recherche PACTE (58) 
Rajah et al. (59) 
Chesebro et al. (60) 
A/C t placebo 
A/C t dipyridamole 
A/C 
A/C t aspirin 
A/C t placebo 
A/C t aspirin 
AIC 
A/C t dipyridamole 
AIC 
MC t dipyridamole 
AIC 
AIC t dipyridamole 
AIC 
AIC t dipyridamole 
A/C t aspirin 
84 
79 
65 
57 
73 
75 
39 
40 
154 
136 
87 
78 
183 
I81 
170 
I4 
I 
20 
5 
I2 
2 
21 
5 
5 
3 
13 
4 
4 
I 
4 
Reduction in embolism (p < 0.01) 
Reduction in embolism (p < 0.05) 
Reduction in embolism (p < 0.01) 
Favorable trend 
Favorable trend 
Favorable trend 
Reduction in embolism (p < 0.05) 
No added benefit* 
* Significant increase in gastrointestinal hemorrhage observed. A/C = anticoagulants; PACTE = Prevention des Accidents Thromboemboliques Systemiques 
Recherche Groupe. 
technically good result from the angioplasty itself, with 
minimal or no postdilation residual stenosis, is important in 
the prevention of restenosis. 
4) Future approaches that may be valuable in reducing 
the rate of restenosis include omega-3 fatty acid therapy, 
thrombin inhibitors, blockers of receptors in smooth muscle 
cells, inhibitors of growth factors that stimulate smooth 
muscle cell proliferation (183), prostacyclin analogues 
(68,69) and monoclonal antibodies against platelet mem- 
brane receptors and adhesive macromolecules, such as von 
Willebrand factor. 
Prosthetic Valve Replacement 
Thrombosis and thromboembolism. There is a long-term 
risk of arterial thromboembolism in patients with prosthetic 
heart valves; progressively fewer patients remain event-free 
over time. In a long-term study (184) of patients with a mitral 
or aortic Starr-Edwards prosthesis, only 66% were free of 
thromboembolic events at 10 years and 58% at 15 years of 
follow-up. Of the embolic events, 85% were cerebral, result- 
ing in a mortality rate of 10%. Forty percent of patients 
having inadequate anticoagulation had thromboembolism. 
Patients with a Bj(irk-Shiley prosthesis have a lower inci- 
dence of thromboembolism, but when thrombotic occlusion 
of the valve occurs, it may lead to acute heart failure. Among 
the mechanical valves, the St. Jude Medical valve has the 
lowest, but nevertheless significant, risk of thromboembo- 
lism. Although bioprosthetic valves are less thrombogenic, 
this complication sometimes occurs, particularly in patients 
not taking anticoagulants with a mitral prosthesis and in 
those with poor left ventricular function, marked left atrial 
enlargement or atria1 fibrillation (185). Overall, there has 
been a reduction in thromboembolism after valve replace- 
ment in recent years, probably because patients are being 
operated on at an earlier stage in their disease process and 
new mechanical prosthetic valves have better hemodynamic 
characteristics. 
Platelet Inhibitor Agents and 
Mechanical Prostheses 
Incidence. Studies (185-187) in patients with mechanical 
valves have consistently shown that appropriate anticoagu- 
lation significantly reduces the incidence of valvular throm- 
bosis and embolism. Without long-term anticoagulation, the 
incidence of thromboembolism increases by two- to sixfold 
(185). Platelet inhibitors alone have not been found to confer 
protection against embolism in patients with mechanical 
prostheses. Several studies (186-188) of aspirin plus dipyr- 
idamole in these patients have shown an incidence of throm- 
boembolism as high as 10% per year. 
Prevention. Because of the persistent risk of thromboem- 
bolism in patients with mechanical prostheses who are 
receiving anticoagulant therapy, the addition of a platelet 
inhibitor has been prospectively studied (56-60,189,190) 
(Table 5). The addition of dipyridamole to an oral anticoag- 
ulant agent was shown to decrease the incidence of throm- 
boembolism in five trials (56-60). The combination of aspirin 
and an oral anticoagulant agent was found to be beneficial in 
two other trials (189,190) but not in a third one (60). 
However, an increased incidence of gastrointestinal bleeding 
was found in one study (60) that used aspirin (500 mg/day) 
plus warfarin. In patients who cannot tolerate dipyridamole, 
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sulfinpyrazone (200 mg four times daily) may be empirically 
added to warfarin, although no randomized prospective 
trials of this combination have been conducted. Uncon- 
trolled studies (83). however, do suggest that this agent is 
effective. 
Anticoagulation is recommended indefinitely to patients with 
prior embolic events or atria1 fibrillation. 
4) Putients with recurrent thromhoembolism despite ad- 
equate antithrombotic therapy should be considered for 
repeat valve replacement. 
Platelet Inhibitor Agents and Bioprostheses 
Mitral bioprostbeses. Although bioprostheses are less 
thrombogenic than mechanical devices, thromboembolism 
still occurs, especially in the first 3 months after surgery, 
more often in patients with a mitral prosthesis and in those 
with atria1 fibrillation or prior embolism (185). These patients 
should receive oral anticoagulation postoperatively for 1 to 3 
months unless atria1 fibrillation persists, in which case long- 
term warfarin therapy is required. Long-term aspirin therapy 
alone has been suggested in patients with a mitral biopros- 
thesis who do not have any of the risk factors of embolism 
just mentioned (191). Valve repair instead of replacement in 
selected patients is rapidly becoming an acceptable alterna- 
tive and is probably associated with a lower incidence of 
thromboembolism. 
Aortic bioprostheses. The appropriate therapy for aortic 
bioprostheses is still controversial. Although some investi- 
gators have recommended warfarin for 3 months, others 
advocate the use of antiplatelet drugs or no therapy at all 
because the embolic risk in these patients is low as long as 
the patient maintains normal sinus rhythm (185). Earlier 
surgical intervention and better protection of the biopros- 
thetic material aimed at preventing valvular degeneration 
have led to increased use of homograft and heterograft 
bioprostheses. 
Current Recommendations 
I) All patients with a mechanical prosthetic heart valve 
require long-term anticoagulant therapy, which should be 
commenced in the early postoperative period. The dose of 
warfarin should be strictly controlled to avoid thromboem- 
bolic or bleeding complications. Therapy is aimed at pro- 
longing the prothrombin time to 1.5 to 2.0 times control 
values (international normalized ratio = 3.0 to 4.5). 
2) Because of the persistent embolic risk, the addition of 
dipyridamole may be beneJicia1 in patients at high risk of 
thromboembolism (those with an old mechanical prosthesis 
or prior embolism). In patients intolerant of dipyridamole, 
sulfinpyrazone and warfarin may be used together, with 
close monitoring of the prothrombin time. The addition of 
aspirin (>500 mgiday) to an anticoagulant agent is contrain- 
dicated because of the significant risk of gastrointestinal 
bleeding. 
3) Patients with a mitral bioprosthesis shouldprobably be 
on anticoagulant therupy for I to 3 months after surgery. 
Cerebrovascular Disease 
Pathogenesis. Approximately 85% of acute strokes are 
ischemic in origin, whereas 15% are due to intracranial 
hemorrhage. Eighty percent of ischemic strokes result from 
atherosclerotic disease in the carotid or large cerebral arter- 
ies by means of embolism of plaque material or platelet-fibrin 
thromboemboli or through the presence of flow-restricting 
stenosis that may lead to thrombosis and occlusion. Of all 
ischemic strokes, only 15% are caused by cardiogenic em- 
boli. These emboli usually arise from thrombus in the left 
atrium, left ventricular surface and native or prosthetic 
mitral or aortic valves (192). 
Platelet Inhibitor Therapy in Stroke 
Antiplatelet therapy. The effectiveness of platelet inhibi- 
tor agents in the secondary prevention of stroke recurrence 
has been controversial. One study (52) showed that aspirin 
had a significant beneficial effect, whereas another large 
randomized study (193) using 1,500 mgiday of aspirin 
failed to demonstrate any benefit in the reduction of 
stroke recurrence or death. In a recent randomized, double- 
blind, placebo-controlled trial (1941, 2,500 patients with a 
recent ischemic neurologic event (60% with stroke, 33% 
with transient ischemic attack and 6% with reversible 
ischemic neurologic deficit) were randomized to aspirin (325 
mg) plus dipyridamole (75 mg) three times daily. After 2 
years. the treated group had a striking 33% reduction in 
event rate (stroke and death) and a 31% reduction in mor- 
tality rate. 
A pooled analysis (131) of 13 randomized trials of anti- 
platelet therapy in cerebrovascular disease (including pa- 
tients with stroke and transient ischemic attacks) clearly 
showed that treatment reduced the incidence of nonfatal 
stroke by 22%. nonfatal myocardial infarction by 35% and 
vascular mortality by 15%. Another platelet inhibitor, ticlo- 
pidine, was found to reduce (by 30%) the combined rates of 
recurrent stroke, myocardial infarction and vascular death in 
a recent randomized, double-blind, placebo-controlled trial 
in patients with recent thromboembolic stroke (80). 
Anticoagulant therapy. With respect to anticoagulant 
therapy in atherothrombotic stroke, several trials (192) have 
shown that this approach is potentially dangerous (because 
of the risk of bleeding) or without benefit and, thus, is not 
recommended. The use of long-term anticoagulant therapy 
in patients with cardiogenic embolism is mandatory and will 
not be discussed further in this review. 
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Table 6. Randomized Controlled Trials of Aspirin in Transient Ischemic Attacks 
Study 
(reference) Therapy 
No. of Follow-up 
Patients (months) 
Stroke/Death 
No. (%) Results of Aspirin Therapy 
AITIA-I (195) Aspirin 88 24 13 (15) Beneficial trend (small trial) 
Placebo 90 19 (21) 
AITIA-II (196) Aspirin 65 24 8 (12) No benefit (small trial) 
Placebo 60 8 (13) 
German (197) Aspirin 29 24 0 (0) No benefit (very small trial) 
Placebo 29 4 (14) 
CCSG (86) Aspirin 290 26 46 (16) Only aspirin was beneficial 
Sulf/Placebo 295 68 (23) (p <0.05) 
Danish (198) Aspirin 101 25 21 (21) No benefit (small trial) 
Placebo 102 17 (17) 
AICLA (52) Aspirin 400 36 35 (9) Reduction in event rate (p < 0.02) 
Placebo 204 31 (15) 
ESPS (194) Aspirin t Dip 1,250 24 190 (IS) Marked reduction in event 
Placebo 1,250 283 (23) rate (p < 0.001) 
UK-TIA (28) Aspirin 1,621 48 171 (II) Reduction in combined vascular 
Placebo 814 109 (13) event rate (p < 0.05) 
AICLA = Accidents Ischemiques Cerebraux lies L’atherosclerose (half of aspirin-treated patients received dipyridamole); AITIA-I = Aspirin in Transient 
Ischemic Attacks (Medical) Trial; AITIA-II = Aspirin in Transient Ischemic Attacks (Surgical) Trial; CCSG = Canadian Cooperative Study Group; Danish = 
Danish Cooperative Study; dip = dipyridamole; ESPS = European Stroke Prevention Study (included patients with stroke and transient ischemic attacks); 
German = German Transient Ischemic Attack Trial; Sulf = sulfmpyrazone; UK-TIA = United Kingdom Transient Ischemic Attack Trial (aspirin doses used: 300 
and 1,200 mglday). 
Platelet Inhibitor 
Ischemic Attacks 
Numerous studies (28,52,86,194-198) have compared as- 
pirin with placebo or other antithrombotic therapy in pa- 
tients with transient ischemic attacks (Table 6). Even though 
the smaller trials (195-198) showed no advantage of aspirin 
over placebo, the small number of patients limits the signif- 
icance of these results. More importantly, all four larger 
trials (28,52,86,194) demonstrated that aspirin significantly 
reduced the rates of stroke and death (Table 6). 
Therapy and Transient 
Aspirin for prevention. Preliminary results from the large 
British randomized, controlled trial of aspirin in transient 
ischemic attacks (UK-TIA) (28) revealed a significant 18% 
reduction in the combined rate of nonfatal stroke, nonfatal 
myocardial infarction and death in patients treated with 
aspirin. However, there was a nonsignificant reduction in the 
incidence of disabling stroke and vascular death. 
In this study, 300 and 1,200 mg of aspirin daily were 
equally effective, but the lower dose was substantially less 
toxic (28). This evidence, coupled with the results of the 
pooled analysis of platelet inhibitor trials in secondary 
prevention of vascular disease (131), clearly suggests that 
aspirin reduces the incidence of stroke and vascular mortal- 
ity in patients with transient ischemic attacks. In a recently 
published randomized study (81) in patients with reversible 
cerebra1 ischemia, ticlopidine was slightly more effective 
than aspirin in preventing fatal and nonfatal strokes. How- 
ever, ticlopidine’s side effects may limit its usefulness. The 
use of anticoagulation in transient ischemic attacks is still 
controversial because both beneficial and harmful trends 
have been observed (192). Therefore, available data support 
only the use of aspirin in patients with transient ischemic 
attacks. 
Current Recommendations 
1) Aspirin is recommended for patients with transient 
ischemic attacks for the prevention of vascular events 
(stroke or myocardial infarction) and vascular mortality. A 
recent study (28) showed that a daily dose of 300 mg is as 
effective as 1,200 mg, but less toxic. 
2) In patients with a completed stroke, the long-term use 
of aspirin has been controversial. However, although the 
recent large European Stroke Prevention Study (194) sug- 
gests that aspirin plus dipyridamole is highly beneficial, 
aspirin alone is probably as effective as the combination with 
dipyridamole (131). 
3) Ticlopidine is proving to be a very efiective agent in 
patients with cerebrovascular disease, according to recently 
published clinical trials (80,81). 
4) Anticoagulant therapy is not recommended for pa- 
tients with a transient ischemic attack or completed stroke. 
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However, patients with cerebral embolism from a cardiac 
source should receive anticoagulant therapy. 
Other Cardiovascular Conditions 
Peripheral vascular disease. The combination of aspirin 
and dipyridamole reduced the progression of peripheral 
atherosclerosis in a 2 year study of patients with peripheral 
vascular disease (199). Other studies (200) suggest a benefi- 
cial effect of ticlopidine in patients with chronic arterial 
insufficiency. Despite encouraging results from some stud- 
ies, there are no convincing data from properly designed, 
large trials showing that antithrombotic therapy delays the 
progression of peripheral vascular disease (201). 
Arteriovenous cannula. Thrombosis of arteriovenous 
cannula results in significant morbidity in patients with 
chronic renal failure on hemodialysis. Anticoagulant agents 
may decrease the incidence of thrombosis but are hazardous 
in uremic patients. Two studies using aspirin (160 mg/day) 
(202) or sulfinpyrazone (82) demonstrated a reduction in the 
incidence of thrombosis of arteriovenous shunts in these 
patients. 
Atrial fibrillation in the absence of valvular heart disease. 
The incidence of stroke is higher in patients with atrial 
fibrillation, even in the absence of valvular heart disease. In 
patients at the highest risk (those with prior embolism, atrial 
fibrillation of recent onset or left ventricular dysfunction), 
the incidence of stroke is 5% per year or even higher (192). 
In these patients. we recommend anticoagulant therapy of 
moderate intensity. Patients at low risk for embolism (for 
example, those with lone atria1 fibrillation) do not require 
anticoagulant therapy. Preliminary evidence from a Danish 
trial (203) of warfarin, aspirin or placebo in patients with 
nonvalvular atria1 fibrillation showed that warfarin signifi- 
cantly reduced the rate of embolic events, whereas aspirin 
was no better than placebo. These findings suggest that in 
atrial fibrillation, blood stasis and fibrin formation are more 
important than platelet-mediated events in the development 
of embolism. 
Mitral valve prolapse. Patients with mitral valve pro- 
lapse, particularly those with a myxomatous valve, are at 
somewhat higher risk of stroke than is the general population 
(204,205). Because the risk is low, prophylaxis is not indi- 
cated in the absence of additional risk factors for embolism. 
If an embolic event occurs or there is evidence of recurrent 
embolism, oral anticoagulation may be empirically insti- 
tuted, although there is no clear evidence that this is bene- 
ficial. 
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